Description: InnoCare Pharma Limited, a biopharmaceutical company, engages in discovering, developing, and commercializing drugs for the treatment of cancer and autoimmune diseases. It develops Orelabrutinib, an BTK inhibitor to treat patients with relapsed and/or refractory (r/r) chronic lymphocytic leukemia, r/r mantle cell lymphoma, r/r Waldenstrom's macroglobulinemia, r/r marginal zone lymphoma, r/r diffuse large B-cell lymphoma (DLBCL)- MCD, r/r central nervous system lymphoma, combo w/MIL-62, systemic lupus erythematosus, immune thrombocytopenia purpura, multiple sclerosis, and neuromyelitis optica spectrum disorder. The company is also developing ICP-192, a pan-FGFR inhibitor that is in a Phase I/II clinical trial for the treatment of solid tumor patients, including cholangiocarcinoma, and head and neck cancer; ICP-723, a pan-TRK inhibitor, which is in Phase I clinical trial to treat neurotrophic tyrosine receptor kinase fusion positive cancers; ICP-332, a novel tyrosine kinase 2 inhibitor that is in a Phase I clinical trial for the treatment of autoimmune diseases; and ICP-B02, a bispecific antibody for the treatment of lymphoma. In addition, it develops ICP-189, ICP-915, and ICP-B03 for the treatment of solid tumors; ICP-033 to treat liver cancer, renal cell carcinoma, colorectal cancer, and other solid tumors; ICP-488 for the treatment of autoimmune diseases; ICP-B05, an anti-CC chemokine receptor 8 monoclonal antibody for the treatment of various cancers; ICP-248 to treat hematology; and ICP-490 for the treatment of hematology and autoimmune diseases. Further, it offers ICP-B04 (Tafasitamab) to treat DLBCL/hematology. InnoCare Pharma Limited was incorporated in 2015 and is headquartered in Beijing, China.
Home Page: www.innocarepharma.com
Building 8
Beijing,
102206
China
Phone:
86 10 6660 9999
Officers
| Name | Title |
|---|---|
| Dr. Jisong Cui Ph.D. | Co-Founder, Exec. Chairperson & CEO |
| Dr. Renbin Zhao Ph.D. | VP of Regulatory Affairs and Clinical Devel. and Exec. Director |
| Mr. Shaojing Tong | Chief Financial Officer |
| Mr. Nan Gao | Chief Operating Officer |
| Dr. Xiangyang Chen Ph.D. | Chief Technology Officer |
| Ms. Junsu Wang | Gen. Counsel |
| Mr. Xiaodong Jin | Chief Commercial Officer |
| Dr. Xiang-Yang Zhang | Chief Medical Officer |
| Dr. Sean Zhang M.D. | Chief Medical Officer |
| Mr. Davy Ouyang Ph.D. | VP & Head of Biology |
Exchange: HK
Country: HK
Currency: Hong Kong Dollar (HK$)
| Forward PE: | 303.0303 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 3.7816 |
| Price-to-Sales TTM: | 47.0518 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 721 |